MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.
We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Ellen Lee Ellen Lee is a ...
Abstract: The high-frequency (HF) pulsating carrier voltage injection method is widely used for sensorless control of permanent magnet synchronous motors operating in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback